Stay updated on Anti-CD38 Antibody Trial in CD38+ Malignancies

Sign up to get notified when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.
Latest website image capture
Clouds background image

Latest updates to the Anti-CD38 Antibody Trial in CD38+ Malignancies page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The record for this completed Phase 1/2 isatuximab study is displayed, including its study design, eligibility criteria, treatment arms, outcome measures, locations, and supporting documents.
    Difference
    100%
    Check dated 2026-11-09T13:28:49.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer now identifies the site revision as v3.8.0 instead of v3.7.2; the study page content remains unavailable.
    Difference
    0.2%
    Check dated 2026-11-02T13:22:05.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A banner announces an NIH-wide transition and says federal agencies are using “Super Intelligence” instead of “Artificial Intelligence,” with both terms appearing during the transition.
    Difference
    1%
    Check dated 2026-10-26T13:49:55.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T13:53:58.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:08:13.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The study record page shows a 403 Forbidden message and a Home link instead of study details.
    Difference
    0.5%
    Check dated 2026-10-05T19:00:26.000Z thumbnail image

Stay in the know with updates to Anti-CD38 Antibody Trial in CD38+ Malignancies

Enter your email address, and we'll notify you when there's something new on the Anti-CD38 Antibody Trial in CD38+ Malignancies page.